Medtronic
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q4).
- Total institutional ownership rose 4.1 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.65% +4.07pp
- Institutions
- 2,658 -6
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Geoffrey Martha | Chairperson & CEO | 0.01% |
| Randall Hogan | Independent Director | 0.00% |
| Brett Wall | Former Officer | 0.00% |
| Craig Arnold | Lead Independent Director | 0.00% |
| Gregory Smith | Former Executive Vice President of Enterprise Operations | 0.00% |
| Matthew Walter | Senior Vice President of Human Resources, IT and Global Communications & Corporate Marketing | 0.00% |
| Sean Salmon | Executive VP & President of Cardiovascular Portfolio | 0.00% |
| Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | 0.00% |
| Kendall Powell | Independent Director | 0.00% |
| Ivan Fong | General Counsel | 0.00% |
| Scott Donnelly | Independent Director | 0.00% |
| Elizabeth Nabel | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | Other Acquisition | +6,547 | -- |
| 2026-11-01 | Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | Other Derivative Acquisition | +16,367 | -- |
| 2026-11-01 | Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | Other Derivative Acquisition | +42,994 | $99.29 |
| 2026-10-14 | Kevin Lofton | Independent Director | Other Disposition | -182 | -- |
| 2026-10-14 | Geoffrey Martha | Chairperson & CEO | Automatic Disposition | -50,000 | $95.00 |
| 2026-10-14 | Geoffrey Martha | Chairperson & CEO | Intent to Sell (Form 144) | -50,000 | $95.00 |
| 2026-10-14 | Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | Automatic Disposition | -10,420 | $96.00 |
| 2026-10-14 | Michael Marinaro | Executive VP and President of Medical Surgical Portfolio & Americas | Intent to Sell (Form 144) | -10,420 | $96.00 |
| 2026-09-15 | Harry Kiil | Executive VP & President of Cardiovascular Portfolio | Open Market Disposition | -1,483 | $93.65 |
| 2026-09-14 | Denise Blomquist | VP, Global Controller & Chief Accounting Officer | Other Disposition | -600 | -- |
| 2026-08-19 | Michael Marinaro | President and President of Medical Surgical Portfolio, Americas & Global Commercial Ops | Sale to Issuer | -1,084 | $92.30 |
| 2026-08-02 | Geoffrey Martha | Chairperson & CEO | Other Acquisition | +41,533 | -- |
| 2026-08-02 | Geoffrey Martha | Chairperson & CEO | Other Derivative Acquisition | +103,831 | -- |
| 2026-08-02 | Geoffrey Martha | Chairperson & CEO | Other Derivative Acquisition | +568,152 | $86.68 |
| 2026-08-02 | Thierry Pieton | Chief Financial Officer | Other Acquisition | +11,537 | -- |
| 2026-08-02 | Thierry Pieton | Chief Financial Officer | Other Derivative Acquisition | +28,842 | -- |
| 2026-08-02 | Thierry Pieton | Chief Financial Officer | Other Derivative Acquisition | +81,945 | $86.68 |
| 2026-08-02 | Harry Kiil | Executive VP & President of Cardiovascular Portfolio | Other Acquisition | +9,230 | -- |
| 2026-08-02 | Harry Kiil | Executive VP & President of Cardiovascular Portfolio | Other Derivative Acquisition | +23,074 | -- |
| 2026-08-02 | Harry Kiil | Executive VP & President of Cardiovascular Portfolio | Other Derivative Acquisition | +65,556 | $86.68 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.
Medtronic discussion 0 comments